Covaxin Is Effective Only 50% Against Delta Variant Of Coronavirus (1st Real-WorldStudy)
The indigenous vaccine developed by ICMR and Bharat Biotech, Covaxin, in a recent study conducted by the All India Institute of Medical Sciences, AIIMS Delhi was found out to provide 50% effectiveness against Covid-19, while the vaccine maker Bharat Biotech claimed the two doses of the vaccine to be 77.8% effective after its phase 3 trials.
The test was conducted between April 15 and May 15, 2021, during the second outbreak of the Covid-19 pandemic and the participants of the test were doctors, nurses and healthcare workers of AIIMS, meaning individuals having greater exposure to the virus. The study was published in The Lancet Infectious Diseases journal.
You can find all the details relating to the study here.
Study Conducted by AIIMS
During the recent outbreak of the second wave of Covid-19 pandemic, AIIMS Delhi conducted a study including 2,714 symptomatic hospital workers, like doctors, nurses and other healthcare workers in the institution, to analyse the effectiveness of Covaxin in the real-world.
This period was marked with the Delta variant of the Covid-19 infection, with 80% positive cases reporting this variant.
In the middle of the peak duration of surging cases and in a hospital environment, having the highest influence of the coronavirus exposure, a total of 2,714 symptomatic hospital workers underwent RT-PCR tests between April 15 and May 15, at least 14 days after getting both the doses of Covaxin.
It was found that of the 2,714 symptomatic individuals, 1,617 tested positive, while 1,097 tested negative for COVID-19. Doctors found this result to be quite positive, as it indicated the effectiveness of the vaccine, in an environment like the hospital’s.
An AIIMS doctor explained that the effectiveness of a vaccine in preventive symptomatic infection increases when the infection rate is low, as the viral load in the environment reduces, thereby lowering the risk of the disease spreading.